Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Korean Patent Office will grant a patent for MycoVa™, indicated for the treatment of onychomycosis (commonly referred to as nail fungus). Specifically, the Korean Patent Office recently issued a “notice of allowance” for the Company’s patent application, entitled, “Antifungal Nail Coat and Method of Use.” Once issued, this will represent the fifth patent that Apricus Bio has received in Asia for MycoVa™ for onychomycosis, and the first in South Korea for this product.
